Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE

Contraception. 2012 Sep;86(3):231-7. doi: 10.1016/j.contraception.2011.12.016. Epub 2012 Mar 23.


Background: Discriminant analysis (DA) was performed on data of two combined hormonal contraceptives (CHC) differing in estrogen ratio to explore whether a combination of variables rather than a single variable distinguishes CHCs better.

Study design: Data were used of a parallel study in premenopausal women treated for three cycles (21 days on, 7 days off) with a contraceptive vaginal ring delivering Nestorone and ethinyl estradiol (EE) or an oral contraceptive containing levonorgestrel and EE. DA was performed on the change from baseline (CFB) and the end-of-treatment values at 3 months for lipids, sex-hormone binding globulin (SHBG), C-reactive protein, angiotensinogen, blood pressure and hemostasis variables, and on the hemostasis variables only.

Results: For the complete set, the CFB for factor VII (FVII), SHBG and plasminogen (PLG), or end-of-treatment SHBG- and FVII level discriminated the treatments best. Maximal discrimination for the hemostasis data was by CFB for FVII and PLG or end-of-treatment FVII level.

Conclusions: DA identifies differences between CHCs and may provide information on the factors associated with thrombotic risk.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Angiotensinogen / drug effects
  • Angiotensinogen / metabolism
  • Blood Coagulation Factors / drug effects*
  • Blood Pressure / drug effects*
  • C-Reactive Protein / drug effects*
  • C-Reactive Protein / metabolism
  • Cholesterol, HDL / drug effects
  • Cholesterol, HDL / metabolism
  • Cholesterol, LDL / drug effects
  • Cholesterol, LDL / metabolism
  • Contraceptive Devices, Female
  • Contraceptives, Oral, Combined / pharmacology*
  • Discriminant Analysis
  • Drug Combinations
  • Ethinyl Estradiol / pharmacology*
  • Female
  • Humans
  • Levonorgestrel / pharmacology*
  • Norprogesterones / pharmacology*
  • Risk
  • Sex Hormone-Binding Globulin / drug effects*
  • Sex Hormone-Binding Globulin / metabolism
  • Thrombosis / chemically induced
  • Thrombosis / epidemiology
  • Triglycerides / metabolism


  • Blood Coagulation Factors
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • Norprogesterones
  • Sex Hormone-Binding Globulin
  • Triglycerides
  • ethinyl estradiol, levonorgestrel drug combination
  • Angiotensinogen
  • Ethinyl Estradiol
  • Levonorgestrel
  • ST 1435
  • C-Reactive Protein